Travere Therapeutics to Present at Multiple Investor Conferences
ByAinvest
Tuesday, Aug 5, 2025 11:06 pm ET1min read
CEPT--
The Canaccord Genuity 45th Annual Growth Conference will take place on Wednesday, August 13, 2025, at 8:00 a.m. ET. The Citi's 2025 Biopharma Back to School Conference is scheduled for Tuesday, September 2, 2025, at 3:15 p.m. ET. Travere will also present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 1:30 p.m. ET, and the Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025, at 2:45 p.m. ET.
Travere Therapeutics is committed to developing life-changing therapies for patients with rare diseases. The company's global team works closely with the rare disease community to identify, develop, and deliver innovative treatments. By participating in these investor conferences, Travere aims to communicate its mission and progress to a broader audience, fostering a deeper understanding of its efforts in the rare disease space.
References:
[1] https://ir.travere.com/press-releases/news-details/2025/Travere-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences-e8c0b6adb/default.aspx
[2] https://www.morningstar.com/news/business-wire/20250805058669/travere-therapeutics-to-participate-at-upcoming-investor-conferences
[3] https://www.marketscreener.com/news/travere-therapeutics-to-participate-at-upcoming-investor-conferences-ce7c5ed8df81f121
TVTX--
WFC--
Travere Therapeutics Inc. (TVTX) will participate in several upcoming investor conferences, including the Canaccord Genuity 45th Annual Growth Conference and the Cantor Global Healthcare Conference 2025. The company will provide live webcasts of its presentations, available on its Investor page. The participation highlights Travere's commitment to communicating its mission and progress in rare disease therapies.
Travere Therapeutics, Inc. (TVTX) has announced its participation in several upcoming investor conferences, including the Canaccord Genuity 45th Annual Growth Conference and the Cantor Global Healthcare Conference 2025. The company will present at these events, providing investors and industry professionals with insights into its mission and progress in rare disease therapies. The presentations will be available live via webcast on Travere's Investor page at ir.travere.com/events-and-presentations, with replays accessible for up to 30 days following each event.The Canaccord Genuity 45th Annual Growth Conference will take place on Wednesday, August 13, 2025, at 8:00 a.m. ET. The Citi's 2025 Biopharma Back to School Conference is scheduled for Tuesday, September 2, 2025, at 3:15 p.m. ET. Travere will also present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 1:30 p.m. ET, and the Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025, at 2:45 p.m. ET.
Travere Therapeutics is committed to developing life-changing therapies for patients with rare diseases. The company's global team works closely with the rare disease community to identify, develop, and deliver innovative treatments. By participating in these investor conferences, Travere aims to communicate its mission and progress to a broader audience, fostering a deeper understanding of its efforts in the rare disease space.
References:
[1] https://ir.travere.com/press-releases/news-details/2025/Travere-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences-e8c0b6adb/default.aspx
[2] https://www.morningstar.com/news/business-wire/20250805058669/travere-therapeutics-to-participate-at-upcoming-investor-conferences
[3] https://www.marketscreener.com/news/travere-therapeutics-to-participate-at-upcoming-investor-conferences-ce7c5ed8df81f121
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet